Frontiers in Endocrinology · 2018 · 122 citations · 37 references
Life SciencesBiochemistryMolecular BiologyEnzymologyMetabolic RegulationMetabolismAllosteric Regulation ModelingEnzyme FunctionEnzyme InhibitionLigand BindingMolecular DockingProtein-ligand DockingAllosteric Site IdentificationAllosteric Site MappingEnzymatic AssaysMechanism-based Enzyme ActivationMechanism-based InhibitionMetformin InteractionsMolecular Docking AnalysisSirtuin 1 Regulation
Metformin has been proposed to operate as an agonist of SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase that mimics most of the metabolic responses to calorie restriction. Herein, we present an in silico analysis focusing on the molecular docking and dynamic simulation of the putative interactions between metformin and SIRT1. Using eight different crystal structures of human SIRT1 protein, our computational approach was able to delineate the putative binding modes of metformin to several pockets inside and outside the central deacetylase catalytic domain. First, metformin was predicted to interact with the very same allosteric site occupied by resveratrol and other sirtuin-activating compounds at the amino-terminal activation domain of SIRT1. Second, metformin was predicted to interact with the NAD+ binding site in a manner slightly different to that of SIRT1 inhibitors containing an indole ring. Third, metformin was predicted to interact with the C-terminal regulatory segment of SIRT1 bound to the NAD+ hydrolysis product ADP-ribose, a “C-pocket”-related mechanism that appears to be essential for mechanism-based activation of SIRT1. Enzymatic assays confirmed that the net biochemical effect of metformin and other biguanides such as a phenformin was to improve the catalytic efficiency of SIRT1 operating in conditions of low NAD+ in vitro. Forthcoming studies should confirm the mechanistic relevance of our computational insights into how the putative binding modes of metformin to SIRT1 could explain its ability to operate as a direct SIRT1-activating compound. These findings might have important implications for understanding how metformin might confer health benefits via maintenance of SIRT1 activity during the aging process when NAD+ levels decline.
37
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Carles Cantó, Zachary Gerhart‐Hines, Jérôme N. Feige et al. · Nature · 2009 · 3.2K citations · Full text
PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation
Péter Bai, Carles Cantó, Hugues Oudart et al. · Cell Metabolism · 2011 · 824 citations · Full text
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer
Daniel Herranz, Maribel Muñoz‐Martín, Marta Cañamero et al. · Nature Communications · 2010 · 608 citations · Full text
Medicine, Biochemistry, Oncology +14